HHS announced Thursday (May 19) that it is committing up to $300 million over 10 years for researching and developing therapeutics, preventatives and diagnostics to combat antimicrobial resistant infections. The department will spend $20 million this year on the initiative, which will be spearheaded by the Boston University-led Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which was launched by the Biomedical Advanced Research and Development Authority (BARDA) in 2016. The Biden administration has been eying ways to develop new antimicrobials. This...